Deerland shared concerns with Gingrey relating to FDA draft guidance.
Deerland Enzymes (Kennesaw, GA) welcomed Georgia Congressman Phil Gingrey to its facility last month. The company reports that it shared concerns with the Congressman relating to current tax policies and FDA’s impending new dietary ingredient (NDI) draft guidance.
As companies await clarity to facilitate the process for establishing NDIs, Deerland Enzymes says that FDA’s current regulatory approach creates innovation challenges more akin to food additive regulations.
“We greatly appreciate Congressman Gingrey taking time out of his busy schedule to tour our facility and truly listen to the challenges we face in our industry,” said company CEO Scott Ravech. “I felt he sincerely understood our concerns and will support us to the best of his ability.”
Deerland Enzymes is a supplier of plant, animal, fungal, and bacterial-sourced enzymes.